Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.
Naoki IwamotoSosuke TsujiAyuko TakataniToshimasa ShimizuShoichi FukuiMasataka UmedaAyako NishinoYoshiro HoraiTomohiro KogaShin-Ya KawashiriToshiyuki AramakiKunihiro IchinoseYasuko HiraiMami TamaiHideki NakamuraKaoru TeradaTomoki OriguchiKatsumi EguchiYukitaka UekiAtsushi KawakamiPublished in: PloS one (2017)
Our present study suggests that tofacitinib is effective in real-world settings even without concomitant MTX use or after switching from TCZ. Our results also suggest that its efficacy diminishes if started after use of multiple bDMARDs.